OneAscent Wealth Management LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

OneAscent Wealth Management LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 452 shares of the biopharmaceutical company’s stock after buying an additional 16 shares during the quarter. OneAscent Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $325,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in REGN. Markel Corp lifted its position in shares of Regeneron Pharmaceuticals by 1.3% in the first quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock valued at $56,083,000 after acquiring an additional 1,000 shares in the last quarter. Cibc World Market Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock valued at $4,481,000 after purchasing an additional 86 shares in the last quarter. Blair William & Co. IL boosted its stake in shares of Regeneron Pharmaceuticals by 18.4% during the 1st quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after purchasing an additional 222 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 23.1% during the first quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 93 shares in the last quarter. Finally, Baird Financial Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 100.9% in the first quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock valued at $25,513,000 after buying an additional 18,345 shares during the last quarter. Hedge funds and other institutional investors own 84.15% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on REGN shares. 22nd Century Group reaffirmed a “downgrade” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 28th. 500.com reiterated a “maintains” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 28th. VNET Group reissued a “downgrade” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 28th. Truist Financial restated a “buy” rating and issued a $1,045.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 16th. Finally, Guggenheim decreased their target price on shares of Regeneron Pharmaceuticals from $935.00 to $900.00 in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $904.00.

Insider Activity

In related news, CFO Robert E. Landry sold 223 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $844.00, for a total value of $188,212.00. Following the sale, the chief financial officer now directly owns 31,699 shares of the company’s stock, valued at $26,753,956. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 223 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $844.00, for a total value of $188,212.00. Following the completion of the transaction, the chief financial officer now owns 31,699 shares of the company’s stock, valued at $26,753,956. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 250 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $710.09, for a total transaction of $177,522.50. Following the sale, the executive vice president now directly owns 20,303 shares in the company, valued at $14,416,957.27. The disclosure for this sale can be found here. In the last three months, insiders sold 32,521 shares of company stock worth $27,232,176. 8.83% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 1.1 %

Regeneron Pharmaceuticals stock traded down $8.98 during midday trading on Friday, hitting $823.40. 1,032,384 shares of the stock were exchanged, compared to its average volume of 446,659. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.45 and a quick ratio of 4.64. The company has a 50 day moving average price of $781.64 and a two-hundred day moving average price of $774.14. The firm has a market cap of $89.39 billion, a P/E ratio of 21.77, a P/E/G ratio of 2.47 and a beta of 0.19. Regeneron Pharmaceuticals, Inc. has a 1 year low of $668.00 and a 1 year high of $847.50.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $10.24 EPS for the quarter, topping the consensus estimate of $8.48 by $1.76. Regeneron Pharmaceuticals had a return on equity of 19.19% and a net margin of 33.93%. The business had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.02 billion. During the same quarter in the previous year, the firm posted $9.77 earnings per share. The company’s revenue was up 10.5% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.42 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.